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Neurovascular dysfunction isanimportantcomponentofAlzheimer’s disease,leadingto reduced clearanceacross theblood-brain
barrier andaccumulationof neurotoxic β-amyloid(Aβ) peptides in thebrain.Ithasbeen shownthatthe ABCtransportprotein P-
glycoprotein (P-gp, ABCB1) is involved in the export of Aβ from the brain into the blood. To determine whether Aβ inﬂuences the
expressionofkeyAβ transporters, westudied theeﬀects of 1-daysubcutaneous Aβ1-40 andAβ1-42administrationvia Alzet mini-
osmotic pumps on P-gp, BCRP, LRP1, and RAGE expression in the brain of 90-day-old male FVB mice. Our results demonstrate
signiﬁcantly reduced P-gp, LRP1, and RAGE mRNA expression in mice treated with Aβ1-42 compared to controls, while BCRP
expression was not aﬀected. The expression of the four proteins was unchanged in mice treated with Aβ1-40 or reverse-sequence
peptides. These ﬁndings indicate that, in addition to the age-related decrease of P-gp expression, Aβ1-42 itself downregulates the
expressionofP-gp and otherAβ-transporters, whichcould exacerbate the intracerebral accumulationofAβ andthereby accelerate
neurodegeneration in Alzheimer’s disease and cerebral β-amyloid angiopathy.
1.Introduction
Burgeoning evidence implicates cerebrovascular dysfunction
in the cognitive decline and neurodegeneration that charac-
terize Alzheimer’s disease (AD) [1, 2]. Impaired clearance of
β-amyloid (Aβ) across the blood-brain barrier (BBB) and
the senescence of the cerebrovascular system are thought
to initiate processes that contribute to neurodegeneration
[1, 3]. The transport of Aβ across the BBB comprises
a two-step process involving transport through the ablu-
minal (brain side) and then through the luminal (blood
side) plasma membranes of the endothelial cells. The low-
density lipoprotein receptor-related protein-1 (LRP1) medi-
ates the incorporation of brain-derived Aβ peptides into the
endothelial cells at the abluminal membrane [4, 5]. On the
otherhand,thereceptorforadvancedglycationendproducts
(RAGE) is considered to be a major inﬂux transporter of
peripherally derived (blood-borne) Aβ into the endothelial
cells of the cerebral vasculature [6, 7]. The ABC transporter
P-glycoprotein (P-gp, ABCB1) is highly expressed at the
luminal side of the endothelial cells that form the BBB, and
may play a key role in the transport of Aβ peptides (either
brain or blood derived) into the blood [8]. In vitro and in
vivoexperiments have shown that P-gp is an active transport
protein for Aβ1-40 and Aβ1-42 [9–14]. These observations
suggest that diminished P-gp expression due to increasing
age, genetic, or environmental factors may lead to impaired
Aβ clearance, followed by the accelerated accumulation of
intracerebral Aβ and eventually the development of AD.
Anautopsystudy ofnondementedelderly humans found
thatvesselswithAβaccumulationwithintheirwalls(cerebral
amyloid angiopathy, CAA) showed little or no endothelial
P-gp expression whereas unaﬀected capillaries had high P-
gp expression, leading to the hypothesis that Aβ leads to
a downregulation of P-gp expression whereas P-gp might
be upregulated in the endothelium of capillaries lacking
Aβ accumulation in an attempt to compensate for the loss
of P-gp in amyloid-bearing vessels [11]. Thus, the aim of2 International Journal of Alzheimer’s Disease
the present study is to investigate the eﬀect of Aβ adminis-
tration on the expression of P-gp and other Aβ transporters
in endothelial cells of the cerebral vasculature.
2.MaterialandMethods
2.1. Laboratory Animals. 90 day-old male FVB wildtype
mice (purchased from Taconic, Hudson, NY, USA) weighing
approximately 25g were used. Animal care and experimental
conditions were conducted in compliance with protocols
approved by the local Animal Care and Use Committee.
2.2. Preparation and Subcutaneous Implantation of ALZET
Mini-Osmotic Pumps. 10–12 animals per group were used
for the systemic administration of Aβ1-40 (DAEFRHDS-
GYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV), Aβ1-42
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVG-
GVVIA), or reverse Aβ40-1 (VVGGVMLGIIAGKNSGVD-
EAFFVLKQHHVEYGSDHRFEAD)or reverse Aβ42-1 (AIV-
VGGVMLGIIAGKNSGVDEAFFVLKQHHVEYGSDHRF-
EAD). All peptides were purchased from AnaSpec Inc. (Fre-
mont, CA, USA).
1mg of each peptide was dissolved in 4μLD M S Oa n d
mixed with 2mL isotonic NaCl solution, yielding a ﬁnal Aβ
concentration of 0.5μg/μL. 200μL( =100μgp e p t i d e )o ft h i s
solution were used to ﬁll the Alzet mini-osmotic pumps.
200μL of isotonic NaCl solution served as vehicle control.
ALZET mini-osmotic pumps (model 2001D; DURECT
Corporation, Cupertino, USA) were implanted subcuta-
neously using a midscapular incision. Pumps delivered syn-
thetic, human-type sequence Aβ1-40, Aβ1-42, reverse Aβ40-
1, Aβ42-1 peptide, or isotonic NaCl solution, respectively.
After a 2-hour start-up transient, the pumps infuse at a
constant pumping rate of 8μLh−1.
After26hmiceweresacriﬁcedbycervicaldislocationand
the brains were immediately removed. One hemisphere was
shock-frozen in liquid nitrogen and stored at −80◦Cu n t i l
use. The other hemisphere was ﬁxed with neutral-buﬀered
4.5% formalin and was embedded in paraﬃn.
2.3. Real-Time PCR Analyses. For real-time PCR analysis,
RNA was isolated from deep-frozen brain tissue using the
RNeasy Mini kit form Qiagen according to the manufac-
turer’s instructions (Qiagen, Hilden, Germany). Reverse
transcription of total-RNA was performed by the TaqMan
reverse transcription kit using random hexamer primers
(AppliedBiosystems, Darmstadt, Germany). Quantitation of
RNA (cDNA) levels for Abcb1a, Abcg2 (Mm00496364 m1),
LRP1 (Mm00464608 m1), as well as RAGE (Mm00545815
m1) and 18SrRNA (part # 4319413E) for normalization was
performed by real-time PCR on a 7900HT TaqMan system
(Applied Biosystems) using predeveloped TaqMan assays
(Assays on Demand, Applied Biosystems). All PCR reactions
were performed in 10μL reactions using a PCR master
mix (2x concentrated) containing 45mmol/L Tris-HCl
(pH 8.4), 115mmol/L KCl, 7mmol/L MgCl2, 460-μmol/L
dNTPs, 9% glycerol, 2.3% ROX reference dye (Invitrogen,
Paisley, Scotland) and 0.035U/mL Platinum Taq DNA
polymerase (Invitrogen). Thermal cycler conditions were
as follows: (50◦C, 2min; 95◦C, 10min followed by 40 cycles
of 95◦C, 15s and 60◦C, 1min).
Expression analysis was performed by the comparative
ΔΔCt-method using the expression of 18SrRNA as reference
gene.
2.4. Immunohistochemistry. For immunohistochemistry,
brain tissues were ﬁxed in neutral-buﬀered, isotonic 4.5%
formalin and embedded in paraﬃn. 1μm-thick tissue sec-
tions were cut, mounted on slides and dried overnight
at 60◦C. For staining, the biotin-streptavidin immunoper-
oxidase method with polymer detection system-HRP
was used. Automated immunohistochemical staining was
performed using the BOND-MAX (Leica) staining systems
using pre-diluted antibodies to murine P-gp (clone C219,
dilution 1:25, pH 9.0, Enzo Life Sciences) and BCRP (clone
BxP53, dilution 1:50, pH 9.0, Enzo Life Sciences).
Negative controls for each treatment were processed
without primary antibody.
2.5. Image Acquisition and Analysis. Digital images were
captured using the Zeiss Mirax Scan Desk slide scanner (Carl
Zeiss MicroImaging GmbH, G¨ ottingen, Germany; Plan-
Apochromat 20x/0.8, pixel resolution: 0.37μm). To quanti-
tate P-gp expression, image analysis algorithms were devel-
oped using ImageJ(version 1.43q, Research ServicesBranch,
National Institute of Mental Health/National Institutes
of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/),
which allowed the identiﬁcation and analysis of immuno-
labeled cerebral capillaries in digital images. The amount
of P-gp-speciﬁc labelling in each animal was determined in
ten high-power ﬁelds (x40) of the brain cortex, the staining
intensity for cortical P-gp of a single animal was the mean of
all measurements.
2.6. Statistical Analysis. Statistical analysis was performed
using Microsoft Excel and GraphPad Prism 5.01 (GraphPad,
San Diego, USA) software using the ΔCt expression values.
The statistical tests employed are indicated in the respective
sections/ﬁgure legends. If the data are represented as box-
plots, the whiskers indicate the 10th and 90th percentiles.
3.Results
First, mRNA expression for P-gp (Abcb1a), BCRP (Abcg2),
LRP1, and RAGE was measured by real-time PCR in mice
treated with Aβ1-42, vehicle control, or the reverse protein
(Aβ42-1) for24h using subcutaneously transplanted ALZET
pumps. Transporter expression was detected in all samples
for Abcb1a and Abcb2 while analysis of LRP1, and RAGE
failed in one Aβ1-42-treated mouse. Signiﬁcant changes in
the expression of Abcb1a, LRP1 and RAGE were detected
in mice given Aβ1-42. While transporter expression was not
signiﬁcantly altered between the control perfusion group
and the mice treated with equal amounts of the reverse
Aβ protein, animals treated with Aβ1-42 had signiﬁcantly
reduced Abcb1a levels in brain (reduced by 63 ± 24% [mean
± SD]) compared to mice given the vehicle control, andInternational Journal of Alzheimer’s Disease 3
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Figure 1: mRNA expression of Abcb1a (a), Abcg2 (b), LRP1 (c), and RAGE (d) in murine brain. Mice were treated with β-amyloid 1-42
(Aβ1-42), reverse β-amyloid 42-1 (Aβ42-1) and vehicle control (control) using ALZET pumps for 24h (4μg/h). mRNA expression of each
transporter was normalized to 18S rRNA expression and values are depicted in relation to the median expression in vehicle perfused mice.
Statistical analysiswas performed by one-way ANOVA followed by Newmann-Keuls Multiple Comparison test.
by 54 ± 30% compared to mice given the reverse-sequence
protein), LRP1 levels (reduced by 57 ± 17%) compared to
vehicle controls and by 60 ± 17% compared to the reverse
protein controls); and RAGE levels (reduced by 65 ± 15%
compared to the reverse protein controls, no signiﬁcant
diﬀerence relative to vehicle controls Figures 1(a), 1(c),a n d
1(d)). In contrast, expression of Abcg2 remained unchanged
in these samples (Figure 1(b)).
Inasecondexperiment,miceweretreatedwithAβ1-40in
a similar manner. Here, no signiﬁcant changes were detected
in any of the four proteins; however, the expression of RAGE
tended to be lower compared to the vehicle control samples
(Figures 2(a)–2(d)).
At the protein level, P-gp and BCRP were detectable
in endothelial cells of brain vessels in all animals using
immunohistochemistry (Figures 3(a) and 3(b)). However,
quantitativelyno changes ofP-gp or BCRPcould be detected
after administration of Aβ1-42 or Aβ1-40 in comparison to
the reverse Aβ peptides or vehicle control, respectively (data
not shown).
4.Discussion
There is growing evidence that an alteration of the transport
of Aβ peptides across the BBB plays a crucial role in
the pathogenesis of AD and CAA. In addition to other
transport proteins such as LRP1 and RAGE, the multidrug
resistance transport protein P-gp is known to eliminate
Aβ1-40 and Aβ1-42 from the brain [12–14]. In nonde-
mented elderlyhumans, Aβ depositionisinversely correlated
with brain capillary P-gp expression [10]. Interestingly,
investigations of the correlation between CAA and P-gp
expression indicate a loss of P-gp in vessels with abundant
cerebrovascular Aβ accumulation. In this study, CAA was4 International Journal of Alzheimer’s Disease
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Figure 2: mRNA expression of Abcb1a (a), Abcg2 (b), LRP1 (c) and RAGE (d) in murine brain. Mice were treated with β-amyloid 1-40
(Aβ1-40),reverse-sequence β-amyloid40-1 (Aβ40-1) andvehiclecontrol (control)usingALZETpumps for24h (4μg/h).mRNA expression
of each transporter wasnormalizedto 18S rRNA expression, andvalues are depicted in relation to the median expression in vehicle-perfused
mice. Statistical analysis was performed by one-way ANOVA followed by Newmann-Keuls Multiple Comparison test.
primarily found in small arteries, but in the advanced stages
of CAA, the capillaries also were aﬀected [11], leading
to the question of how Aβ itself aﬀects P-gp expression
in the endothelial cells that are a key component of the
BBB.
The present study found that peripherally administered
Aβ1-42 leads to a decrease of P-gp expression in vivo
in mouse brains at the mRNA level. This ﬁnding is in
concordance with the results of Hartz et al., who reported
that P-gp expression and transport activity are compromised
in brain capillaries isolated from hAPP transgenic mice that
exhibit accumulation of human-type Aβ within the brain
[14]. Thus, it can be hypothesized that the compromising
eﬀect of Aβ on P-gp expression leads to a further increase
of Aβ accumulation, thus initiating a vicious circle that
exacerbates the progression of the disease.
LRP1 is localized at the brain-side membrane of capil-
laries; as a receptor for Aβ,L R P 1m e d i a t e st h et r a n s p o r to f
the peptide from the brain into the endothelial cells. LRP1
expression was reported to be reduced during normal aging
in animals and in AD patients associated with accumulation
of Aβ1-40 and Aβ1-42 within the cerebral vessels [4, 15,
16]. Our results revealed signiﬁcantly reduced levels of
LRP1 mRNA in mice treated with Aβ1-42, conﬁrming
the lowering eﬀect of Aβ on LRP1 expression. However,
12-week-old hAPP mice revealed slightly increased LRP1
expression whereas RAGE was unchanged, suggesting the
critical limiting step in Aβ brain clearance could be P-
gp-mediated Aβ transport across the luminal endothelial
membrane into the blood [14].
RAGE is normally expressed at the luminal side of the
endothelial cells, and mediates the transport of Aβ1-40 andInternational Journal of Alzheimer’s Disease 5
(a) (b)
Figure 3: Immunohistochemical expression of P-gp (a) and BCRP (b) in endothelial cells of mice brain capillaries (original magniﬁcation
×200).
Aβ1-42 from blood into the endothelium [6]. In AD and AD
models, cerebrovascular RAGE was shown to be increased
[17]. Our results show that mRNA levels were signiﬁcantly
reduced in mice treated with Aβ1-42 in comparison to the
reverse-sequence peptide. Relative to the vehicle control,
RAGE mRNA expression showed a trend to be reduced by
Aβ1-42, but did not reach statistical signiﬁcance. However,
ourﬁndingsareinconcordancewiththeobservationthatthe
expression ofRAGE inBrown-Norway/Fischerrats decreases
in early stages of Aβ accumulation and increases with
advanced age [18]. This suggests that an increase of RAGE
expression plays a role in the later stages but not in the
initiation of AD.
Our results show that Aβ1-42, but not Aβ1-40, inhibits
P-gp, LRP1 and RAGE expression at the BBB. Under
physiological conditions, the ratio of Aβ1-42 to Aβ1-40 in
the brain is about 1:10 [19]. Thus, the amount of Aβ1-40
in our pumps might have been too low to achieve suﬃcient
eﬀects on P-gp expression at the capillary endothelial cells.
However, since the aggregative ability and the neurotoxicity
of Aβ1-42 are much greater than those of Aβ1-40, Aβ1-
42 plays a more important role in the pathogenesis of AD
[19, 20]. In this regard, Aβ1-42 was reported to induce
free radical-related oxidative stress and neurodegeneration
in AD brains [21]. Interestingly, in contrast to Aβ1-40,
the concentration of free Aβ1-42 in cerebrospinal ﬂuid is
lower in patients with AD, suggesting that Aβ1-42 might be
preferentially incorporated into growing plaques [20].
In our study, the decrease of P-gp expression was
observed at the mRNA level but not at the protein level
using immunohistochemistry. This might beduetotheshort
period during which Aβ is present within the blood, leading
to acute eﬀects of Aβ on transcription processes that were
not reﬂected in changes of protein expression within this
timeframe. Possibly, a longer treatment period is necessary
to address this question.
LikeP-gp,BCRPislocalizedattheluminalsiteofvascular
endothelial cells and contributes to the integrity of the blood
brain barrier (BBB), thus protecting the brain parenchyma
from the damaging eﬀects of xenobiotics [22]. P-gp and
BCRP share extensive similarities regarding their substrate
speciﬁcity,andthelistofsubstratesofBCRPhasbeensteadily
expanding since its discovery [23]. Using a human brain
endothelial cell line (hCMEC/D3) Aβ1-40 has been shown
to be a substrate of BCRP [24]. Xiong et al. reported that
BCRP mediates the transport of Aβ in BCRP-overexpressing
cell lines, and that Aβ accumulates in the brains of BCRP-
knockout mice. On the other hand, BCRP expression was
increased in brain tissue of AD cases [25]. However, in the
present study we found BCRP expression to be unchanged
by circulating Aβ. This is in agreement with the ﬁndings on
young hAPP mice, where no evidence was found for BCRP-
mediated Aβ transport in brain capillaries [14]. Thus, it can
behypothesisedthatBCRP,likeRAGE,mightnotbeinvolved
in the early stages of AD, but rather may play a role in more
advanced stages of the disease.
5.Conclusions
These ﬁndings lend further support for the involvement
of the ABC transport protein P-gp in the transport of Aβ
across the BBB. Speciﬁcally, circulating Aβ itself lowers P-
gp expression at the BBB, leading to a circulus vitiosus
that triggers further Aβ accumulation. The activity of P-
gp is well known to be modulated pharmacologically by a
range of commonly used drugs [26–28]. Thus, restoring P-
gp function could be a novel therapeutic strategy to protect
the brain from Aβ accumulation, and thus could be a tool to
prevent and/or slow the progression of CNS disorders such
as Alzheimer’s disease.
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